论文部分内容阅读
基于配体竞争反应提出了抗癌药物巯嘌呤的荧光分析法.研究发现,在pH=6.8的HEPES缓冲中,Cu2+能与荧光小分子2,6-双(2-苯并咪唑)吡啶(Bbimp)形成非荧光配合物Cu2+-Bbimp,但当抗癌药物巯嘌呤(MP)存在时,由于MP中的巯基(—SH)与Cu2+发生强烈作用而发生配体竞争,游离出的Bbimp的荧光与MP具有函数关系.据此建立了MP的荧光分析方法,线性范围为4.0×10-6～7.0×10-5 mol/L,检测限为3.0×10-7 mol/L.该方法成功用于人体尿样中MP的分析,回收率在96.7%～107.3%之间,相对标准偏差(RSD)小于1.97%.测定结果与药典标准方法一致.
Fluorescence analysis of mercaptopurine, an anticancer drug, was proposed based on the competition of ligands.It was found that in the HEPES buffer solution with pH = 6.8, Cu2 + could interact with fluorescent small molecule 2,6-bis (2-benzimidazole) pyridine ) Forms a non-fluorescent complex Cu2 + -Bbimp. However, when the anti-cancer drug mercaptopurine (MP) is present, ligand competition occurs due to strong interaction between sulfhydryl (-SH) in MP and Cu2 + MP has a functional relationship.Accordingly, a fluorescence analysis method was established for MP with a linear range of 4.0 × 10-6 ~ 7.0 × 10-5 mol / L and a detection limit of 3.0 × 10-7 mol / L. The method was successfully applied to The analysis of MP in human urine samples showed that the recovery rates were between 96.7% and 107.3%, and the relative standard deviations (RSDs) were less than 1.97%.